IDH2 and chondrosarcoma: More recently, studies carried out with CRISPR/Cas9 technology [125] and with a new IDH mutation inhibitor, the DS-1001b [126], demonstrate the importance of this mutation in the tumorigenicity of chondrosarcoma, and therefore the interest in targeting this mutation for chondrosarcoma treatment.